1. Home
  2. PCSA vs UPC Comparison

PCSA vs UPC Comparison

Compare PCSA & UPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCSA
  • UPC
  • Stock Information
  • Founded
  • PCSA 2011
  • UPC 1998
  • Country
  • PCSA United States
  • UPC China
  • Employees
  • PCSA 13
  • UPC N/A
  • Industry
  • PCSA Biotechnology: Pharmaceutical Preparations
  • UPC Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCSA Health Care
  • UPC Health Care
  • Exchange
  • PCSA Nasdaq
  • UPC Nasdaq
  • Market Cap
  • PCSA 1.2M
  • UPC 1.3M
  • IPO Year
  • PCSA N/A
  • UPC 2021
  • Fundamental
  • Price
  • PCSA $0.24
  • UPC $3.97
  • Analyst Decision
  • PCSA Strong Buy
  • UPC
  • Analyst Count
  • PCSA 1
  • UPC 0
  • Target Price
  • PCSA $6.00
  • UPC N/A
  • AVG Volume (30 Days)
  • PCSA 6.0M
  • UPC 393.3K
  • Earning Date
  • PCSA 05-09-2025
  • UPC 05-02-2025
  • Dividend Yield
  • PCSA N/A
  • UPC N/A
  • EPS Growth
  • PCSA N/A
  • UPC N/A
  • EPS
  • PCSA N/A
  • UPC N/A
  • Revenue
  • PCSA N/A
  • UPC $26,725,919.00
  • Revenue This Year
  • PCSA N/A
  • UPC N/A
  • Revenue Next Year
  • PCSA N/A
  • UPC N/A
  • P/E Ratio
  • PCSA N/A
  • UPC N/A
  • Revenue Growth
  • PCSA N/A
  • UPC N/A
  • 52 Week Low
  • PCSA $0.22
  • UPC $2.51
  • 52 Week High
  • PCSA $3.10
  • UPC $2,592.00
  • Technical
  • Relative Strength Index (RSI)
  • PCSA 32.49
  • UPC 45.86
  • Support Level
  • PCSA $0.20
  • UPC $3.61
  • Resistance Level
  • PCSA $0.25
  • UPC $5.47
  • Average True Range (ATR)
  • PCSA 0.06
  • UPC 0.87
  • MACD
  • PCSA 0.01
  • UPC 0.23
  • Stochastic Oscillator
  • PCSA 32.69
  • UPC 39.96

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About UPC Universe Pharmaceuticals Inc.

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Share on Social Networks: